Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Baxter International Inc.NYSE: BAX
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of $156M (cash outflow) rose 136.4% year over year, ahead of the +21.5% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +40.1% a year.
Context
- Accounts receivables amounted to 1.2% of revenue in FY2025, up 0.8 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +136.4% holds above the trailing-twelve-month pace of +21.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (132M) USD
- Year-over-year change
- -277.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (132M) | -277.1% |
| FY2024 | 2024-12-31 | (35M) | +7.9% |
| FY2023 | 2023-12-31 | (38M) | +20.8% |
| FY2022 | 2022-12-31 | (48M) | +71.8% |
| FY2021 | 2021-12-31 | (170M) | — |
Accounts Receivables vs competitors
How BAX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.5% is the 3rd highest of 5, against a peer median of +23.0%.
- Accounts receivables amounts to 0.8% of revenue for BAX, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $96M USD | +21.5% | +40.1% | 0.8% | |
| LTM Jun 2026 | €93.4M EUR | -124.5% | +12.4% | 0.5% | |
| LTM Jun 2026 | $53.62M USD | +142.9% | +12.4% | 0.4% | |
| LTM Jun 2026 | $15.38M USD | -58.3% | — | 0.7% | |
| LTM Mar 2026 | $108K USD | +104.2% | — | 0.1% | |
| Peer median (excluding BAX) | — | +23.0% | +12.4% | 0.4% | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.03B | (3.11B) | 181M | (326M) | (957M) |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| Deferred Income Tax | (161M) | (260M) | (256M) | (262M) | 77M |
| Stock-Based Compensation | 146M | 140M | 115M | 114M | 117M |
| Change in Working Capital | (57M) | (606M) | 161M | (236M) | (108M) |
| Accounts Receivables | (170M) | (48M) | (38M) | (35M) | (132M) |
| Inventory | (27M) | (198M) | (128M) | (201M) | (119M) |
| Accounts Payables | 105M | (67M) | 92M | 112M | 3M |
| Other Working Capital | 35M | (293M) | 235M | (112M) | 140M |
| Other Non-Cash Items | 394M | 3.98B | 541M | 732M | 735M |
| Operating Cash Flow | 2.22B | 1.21B | 1.73B | 1.02B | 845M |
| Capital Expenditures | (691M) | (635M) | (436M) | (460M) | (522M) |
| Acquisitions (Net) | (10.5B) | (263M) | (6M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 34M | 0 |
| Other Investing Activities | (7M) | (33M) | 3.66B | (200M) | 3.35B |
| Investing Cash Flow | (11.2B) | (931M) | 3.21B | (626M) | 2.84B |
| Debt Repayment | 9.33B | (899M) | (2.94B) | (531M) | (3.79B) |
| Common Stock Issued | 187M | 127M | 95M | 71M | 30M |
| Common Stock Repurchased | (600M) | (32M) | 0 | 0 | 0 |
| Dividends Paid | (530M) | (573M) | (586M) | (590M) | (348M) |
| Other Financing Activities | (138M) | (61M) | (63M) | (31M) | (107M) |
| Financing Cash Flow | 8.25B | (1.44B) | (3.49B) | (1.08B) | (4.22B) |
| Effect of Forex Changes | (47M) | (76M) | 26M | (96M) | 84M |
| Net Change in Cash | (780M) | (1.23B) | 1.48B | (784M) | (446M) |
| Free Cash Flow | 1.53B | 576M | 1.29B | 559M | 323M |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.